In the past week, RLAY stock has gone up by 13.16%, with a monthly gain of 1.14% and a quarterly plunge of -32.47%. The volatility ratio for the week is 6.06%, and the volatility levels for the last 30 days are 6.38% for Relay Therapeutics Inc. The simple moving average for the past 20 days is 6.33% for RLAY’s stock, with a -37.31% simple moving average for the past 200 days.
Is It Worth Investing in Relay Therapeutics Inc. (NASDAQ: RLAY) Right Now?
There are mixed opinions on the stock, with 11 analysts rating it as a “buy,” 0 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
The average price estimated by analysts for RLAY is $28.38, which is $16.8 above than the current price. The public float for RLAY is 118.14M, and at present, short sellers hold a 18.18% of that float. The average trading volume of RLAY on May 25, 2023 was 1.62M shares.
RLAY) stock’s latest price update
Relay Therapeutics Inc. (NASDAQ: RLAY) has seen a decline in its stock price by -0.43 in relation to its previous close of 11.57. However, the company has experienced a 13.16% gain in its stock price over the last five trading sessions.
RLAY Trading at -15.40% from the 50-Day Moving Average
After a stumble in the market that brought RLAY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.15% of loss for the given period.
Volatility was left at 6.38%, however, over the last 30 days, the volatility rate increased by 6.06%, as shares surge +1.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.33% lower at present.
During the last 5 trading sessions, RLAY rose by +12.92%, which changed the moving average for the period of 200-days by -38.53% in comparison to the 20-day moving average, which settled at $10.84. In addition, Relay Therapeutics Inc. saw -22.89% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RLAY starting from Bergstrom Donald A, who sale 1,383 shares at the price of $11.16 back on Apr 28. After this action, Bergstrom Donald A now owns 242,701 shares of Relay Therapeutics Inc., valued at $15,434 using the latest closing price.
Adams Brian, the Chief Legal Officer of Relay Therapeutics Inc., sale 863 shares at $11.16 during a trade that took place back on Apr 28, which means that Adams Brian is holding 134,882 shares at $9,631 based on the most recent closing price.
Stock Fundamentals for RLAY
Current profitability levels for the company are sitting at:
- -22516.44 for the present operating margin
- -199.06 for the gross margin
The net margin for Relay Therapeutics Inc. stands at -21036.13. The total capital return value is set at -32.25, while invested capital returns managed to touch -30.22. Equity return is now at value -35.70, with -30.80 for asset returns.
Based on Relay Therapeutics Inc. (RLAY), the company’s capital structure generated 6.08 points at debt to equity in total, while total debt to capital is 5.73. Total debt to assets is 5.25, with long-term debt to equity ratio resting at 5.63. Finally, the long-term debt to capital ratio is 5.30.
When we switch over and look at the enterprise to sales, we see a ratio of 405.47, with the company’s debt to enterprise value settled at 0.08. The receivables turnover for the company is 0.27 and the total asset turnover is 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.00.
Conclusion
In summary, Relay Therapeutics Inc. (RLAY) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
